Uncontrolled, Open-label, Non-randomized, Phase 1 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2013
At a glance
- Drugs Regorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Apr 2012 Actual patient number (33) added as reported by ClinicalTrials.gov.
- 19 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.